中老年女性类风湿关节炎患者卵巢癌风险的危险因素分析

doi:10.20047/j.issn1673-7210.2022.29.23

Abstract
Figure/Table
References (28)
Related Citation (15)

Download: PDF (891 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To study the risk factors of ovarian cancer risk in middle-aged and elderly women with rheumatoid arthritis (RA). Methods A total of 180 middle-aged and elderly (age ≥40) female RA patients (RA group) admitted to the Second Affiliated Hospital of Guizhou University of Traditional Chinese Medicine from October 2019 to December 2020 and 80 healthy middle-aged and elderly females (healthy group) were randomly selected. The general conditions of subjects and ovarian cancer risk-related indicators of RA patients were recorded. The absolute value of T lymphocyte subsets of RA patients were detected. The levels of CA125 in the two groups were compared. The RA group was divided into 31 cases of CA125 positive group and 149 cases of CA125 negative group according to whether CA125 was abnormal or not. The correlation between the elevation of CA125 in RA patients and human epididymal protein 4 (HE4) and T cell subsets was analyzed. Results The CA125 level in the RA group was higher than that in the healthy group (P ＜ 0.05). The levels of HE4 and CD8+ T cells in CA125-positive patients were significantly higher than those in CA125-negative patients (P ＜ 0.05). Logistic regression analysis showed that HE4 (OR = 1.117, 95%CI:1.052-1.185) and CD8+ T cells (OR = 1.499, 95%CI:1.213-1.851) were independent risk factors for CA125 positivity in RA patients (P ＜ 0.05). Conclusion Middle-aged and elderly female RA patients are prone to CA125 positivity. CA125 positivity is closely related to the levels of HE4 and CD8+ T cells, which may indicate an increased risk of ovarian cancer in CA125-positive RA patients. Clinically, the risk of ovarian cancer in this population should be fully paid attention to and timely investigation should be carried out.

Key words： Rheumatoid arthritis CA125 Human epididymal protein 4 T cell subsets Ovarian cancer

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	HUANG Zhaowei1 Ling Yi2 Tan Linlin3 HUANG Fangqin1 WANG Lu1 MA Wukai2

Cite this article:

HUANG Zhaowei1 Ling Yi2 Tan Linlin3 HUANG Fangqin1 WANG Lu1 MA Wukai2. Analysis of risk factors for ovarian cancer risk in middle-aged and elderly female with rheumatoid arthritis[J]. 中国医药导报, 2022, 19(29): 101-104,125.

URL:

https://www.yiyaodaobao.com.cn/EN/10.20047/j.issn1673-7210.2022.29.23 OR https://www.yiyaodaobao.com.cn/EN/Y2022/V19/I29/101

[1] 周新朋，金晔华，张润润，等.类风湿关节炎成纤维样滑膜细胞lncRNA-miRNA-mRNA网络构建及关键基因预测[J].中国医药导报，2021，18（9）：12-16，197.
[2] Pundole X，Suarez-Almazor ME. Cancer and Rheumatoid Arthritis [J]. Rheum Dis Clin North Am，2020，46（3）：445-462.
[3] De Cock D，Hyrich K. Malignancy and rheumatoid arthritis：Epidemiology，risk factors and management [J]. Best Pract Res Clin Rheumatol，2018，32（6）：869-886.
[4] Klein A，Polliack A，Gafter-Gvili A. Rheumatoid arthritis and lymphoma：Incidence，pathogenesis，biology，and outcome [J]. Hematol Oncol，2018，36（5）：733-739.
[5] Lim XR，Xiang W，Tan JWL，et al. Incidence and patterns of malignancies in a multi-ethnic cohort of rheumatoid arthritis patients [J]. Int J Rheum Dis，2019，22（9）：1679-1685.
[6] Morand S，Staats H，Creeden JF，et al. Molecular mechanisms underlying rheumatoid arthritis and cancer development and treatment [J]. Future Oncol，2020，16（9）：483-495.
[7] ■wierkot J，Lewandowicz-Uszyńska A，Bogunia-Kubik K. Tumors in rheumatic diseases [J]. Postepy Hig Med Dosw （Online），2013，67：1254-1260.
[8] Inose R，Hashimoto N，Hosomi K，et al. Association between malignancy and methotrexate and biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis [J]. Int J Clin Pharmacol Ther，2020， 58（3）：131-138.
[9] 李娜，代聪伟，杨艳艳，等.MFG-E8对卵巢癌SKOV3细胞顺铂敏感度的影响及分子机制[J].肿瘤防治研究，2021，48（5）：464-469.
[10] 赵爽，孙静莉.卵巢癌组织中miR-410、CCNB1的表达及临床意义[J].中国医药导报，2021，18（11）：105-108.
[11] 来金欣，叶嘉琪，陈杰荣，等.血清糖类抗原125联合人附睾蛋白4及糖类抗原199检测诊断上皮性卵巢癌的意义[J].中国妇幼保健，2020，35（24）：4674-4677.
[12] Dochez V，Caillon H，Vaucel E，et al. Biomarkers and algorithms for diagnosis of ovarian cancer：CA125，HE4，RMI and ROMA，a review [J]. J Ovarian Res，2019，12（1）：28.
[13] Kim B，Park Y，Kim B，et al. Diagnostic performance of CA 125，HE4，and risk of Ovarian Malignancy Algorithm for ovarian cancer [J]. J Clin Lab Anal，2019，33（1）：e22624.
[14] 张洞云，邵旭，袁彤，等.联合检测外周血T淋巴细胞亚群及血清CA125在卵巢良、恶性肿瘤鉴别及卵巢癌早期诊断中的应用[J].现代诊断与治疗，2007（3）：133-136.
[15] Samuel B，Edelton M，Maria B，et al. Tumor markers are elevated in patients with rheumatoid arthritis and do not indicate presence of cancer [J]. Int J Rheum Dis，2012， 15（2）：179-182.
[16] 王娟，陈友国，查雪丽，等.93例复发性卵巢癌疗效分析[J].肿瘤防治研究，2020，47（1）：58-62.
[17] 辛玉琦，巨宇叶，王晓慧.卵巢癌生物标志物及早期诊断的研究进展[J].国际妇产科学杂志，2020，47（5）：544-549.
[18] 陈轶杰，魏志环，李晓茹.三维超声联合ROMA指数在卵巢良恶性肿瘤鉴别中的应用价值[J].现代肿瘤医学，2021，29（8）：1361-1364.
[19] 陈咏宁，张雅迪，陈莉，等.血清CA125、HE4及基于二者的ROMA、CPH-I在卵巢肿瘤良恶性鉴别诊断中的应用价值[J].中国医药导报，2019，16（17）：9-12，22.
[20] Chen L，Yang X，Abasi X，et al. The diagnostic，prediction of postoperative recurrence and prognostic value of HE4 in epithelial ovarian cancer [J]. J BUON，2018，23（2）：428-432.
[21] 邓森灵，兰代群，曹雅文，等.血清miR-222、HE4及CA125水平联合ROMA指数对上皮性卵巢癌的诊断价值[J].现代妇产科进展，2021，30（3）：189-192.
[22] Gentry-Maharaj A，Blyuss O，Ryan A，et al. Multi-Marker Longitudinal Algorithms Incorporating HE4 and CA125 in Ovarian Cancer Screening of Postmenopausal Women [J]. Cancers（Basel），2020，12（7）：1931.
[23] 门文婷，韩春颖，刘珊珊，等.子宫内膜异位症与卵巢癌关系的研究进展[J].国际妇产科学杂志，2019，46（2）：138-141.
[24] Rekha K，Ashok M. Interplay between inflammation and cancer [J]. Adv Protein Chem Struct Biol，2020，119：199-245.
[25] Winkler I，Wo■ J，Karczmarczyk A，et al. An association of circulating Tregs and Th17 cells producing IL-21 and IL-22 with the ROMA in ovarian cancer patients [J]. Cytokine，2020，134：155194.
[26] Paradowska-Gorycka A，Wajda A，Romanowska-Próchnicka K，et al. Th17/Treg-Related Transcriptional Factor Expression and Cytokine Profile in Patients With Rheumatoid Arthritis [J]. Front Immunol，2020，11：572858.
[27] 栾仲秋，向月，李秋红，王继坤.槐米提取物对类风湿关节炎大鼠Th17/Treg细胞平衡的调节作用[J].中国医药导报，2019，16（20）：25-28.
[28] Fang G，Liu J，Wang Q，et al. MicroRNA-223-3p Regulates Ovarian Cancer Cell Proliferation and Invasion by Targeting SOX11 Expression [J]. Int J Mol Sci，2017，18（6）：1208.